Impairment Risks for Deferred Tax Assets and Fixed Assets
First written in FY2020. 11 of 12 entries say "Materialised", first in FY2021-Q3. Latest entry: FY2026.
Ono Pharmaceutical moved to the "Worse" side of this theme in 2021, 1 year after the typical company in this theme (2020).
The whole theme swung hardest in 2020: 5 of 10 companies on the "Worse" side.
2 other companies' latest entry also says "Materialised".
- FY2026MaterialisedAnnual report
「As a result of impairment testing, impairment losses of ¥6,000 million on in-process R&D were recognized in the previous consolidated fiscal year and ¥1,939 million in the current consolidated fiscal year. The impairment losses on in-process R&D were recognized following the discontinuation of development of a new drug.」
An impairment loss of ¥1,939 million was recognized on in-process R&D, resulting in asset impairment following the discontinuation of development, as in the previous fiscal year. - FY2025MaterialisedAnnual report
「As a result of impairment testing, impairment losses were recognized in the previous consolidated fiscal year on marketing rights, mainly for JOYCLU intra-articular injection and Parsabiv intravenous injection for dialysis, in the amount of ¥11,134 million, and on in-process R&D in the amount of ¥3,700 million. In the current consolidated fiscal year, an impairment loss of ¥6,000 million was recognized on in-process R&D.」
An impairment loss of ¥6.0 billion was recognized on in-process R&D, and the R&D investment risk associated with discontinuing development crystallized again in the current fiscal year. - FY2025-H1MaterialisedAnnual report
「We recorded an impairment loss of ¥3,500 million on in-process research and development resulting from the decision not to exercise the option under the asset acquisition agreement with an exclusive option relating to itolizumab. The loss was included in research and development expenses in the condensed interim consolidated statement of income.」
Following the decision not to exercise the option on itolizumab, an impairment loss of ¥3.5 billion was recognized on in-process R&D, crystallizing the R&D investment risk. - FY2024MaterialisedAnnual report
「In the current fiscal year, we recognized impairment losses of ¥11,134 million on marketing rights, mainly for Joyclu Joint Injection and Parsabiv Intravenous Injection for Dialysis, and ¥3,700 million on in-process research and development.」
The impairment loss on marketing rights disclosed through the previous quarter expanded to ¥11,134 million for the full year, and an impairment loss of ¥3,700 million was also recognized on in-process research and development. - FY2024-Q2MaterialisedAnnual report
「We recorded an impairment loss of ¥5,421 million on the marketing rights for Joyclu Joint Injection and Edarbi Tablets, which was included in cost of sales in the condensed interim consolidated statement of income.」
Due to a decline in the profitability of the marketing rights, an impairment loss of ¥5,421 million was recognized for Joyclu Joint Injection and Edarbi Tablets. - FY2024-Q1MaterialisedAnnual report
「Impairment loss － ¥19 million」
An impairment loss of ¥19 million was reported in the cash flow statement for the cumulative first quarter, indicating that asset impairment continued to occur. - FY2023MaterialisedAnnual report
「Our Group recorded impairment losses on property, plant and equipment of ¥498 million in the previous fiscal year and ¥1,498 million in the current fiscal year, and recognized an impairment loss of ¥1,000 million on marketing rights in the current fiscal year.」
Impairment losses, including ¥498 million on property, plant and equipment and ¥1,000 million on marketing rights, were recognized, indicating that the asset impairment risk continued to materialize. - FY2023-Q3MaterialisedAnnual report
「Impairment loss 345 1,154」
An impairment loss of ¥1,154 million was reported in the cash flow statement for the cumulative third quarter, indicating that asset impairment continued to occur. - FY2022MaterialisedAnnual report
「Our Group recognized impairment losses of ¥316 million on property, plant and equipment in the previous fiscal year and ¥3,404 million in the current fiscal year. For intangible assets, we recognized an impairment loss of ¥3,088 million on in-process research and development in the current fiscal year.」
In the fiscal year ended March 2022, total impairment losses on property, plant and equipment and intangible assets amounted to ¥3,404 million, indicating that the risk of impairment of deferred tax assets and other assets continued to materialize. - FY2022-Q2MaterialisedAnnual report
「Impairment loss - 124」
An impairment loss of ¥124 million was reported in the cash flow statement for the cumulative second quarter, indicating that asset impairment continued to occur. - FY2021-Q3MaterialisedAnnual report
「We recognized impairment losses of ¥2,305 million in the cumulative third quarter. The impairment loss on marketing rights was included in cost of sales, and the impairment loss on in-process research and development was included in research and development expenses in the condensed interim consolidated statement of income. The impairment loss on in-process research and development was recognized following the discontinuation of development of a new drug.」
Total impairment losses of ¥2,305 million were recognized on marketing rights and in-process research and development, confirming that the asset impairment previously disclosed as a risk had materialized. - FY2020First statedAnnual report
「If various risks described under "Business and Other Risks" materialize, causing a gap from the business plan and preventing us from generating the cash flows expected in the future, property, plant and equipment and intangible assets may be impaired, or deferred tax assets may decrease.」
Decreases in deferred tax assets and impairment of property, plant and equipment and intangible assets were explicitly identified for the first time as separate risks associated with deviations from the business plan.